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Obesity surgery remains the most effective treatment for obesity and its 
complications. Weight loss was initially attributed to decreased energy absorption 
from the gut but have since been linked to reduced appetitive behaviour and 
potentially increased energy expenditure. Implicated mechanisms associating 
rearrangement of the gastrointestinal tract with these metabolic outcomes include 
central appetite control, release of gut peptides, change in microbiota and bile acids. 
However, the exact combination and timing of signals remain largely unknown. In 
this review, we survey recent research investigating these mechanisms, and seek to 
provide insights on unanswered questions over how weight loss is achieved 
following bariatric surgery which may eventually lead to safer, nonsurgical weight-
loss interventions or combinations of medications with surgery. 
 






































Obesity surgery over the past six decades has been successful not only in providing 
a means of achieving substantial weight loss but also in giving us many novel 
insights on the pathophysiology of obesity. Obesity surgery was first described in the 
1960s, when it was observed that patients with sub-total gastrectomy for cancer lost 
a considerable amount of weight 1. Several modifications to the technique led to the 
first laparoscopic gastric bypass in 1994 2, and the establishment of the three 
techniques most widely-used in clinical practice today.  
The two main approaches that are currently performed widely are Roux-en-Y Gastric 
Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG). RYGB involves the 
creation of a small gastric pouch (~30 mL) that is anastomosed to the proximal 
jejunum, which has been transected at 30–75 cm from the ligament of Treitz, to form 
the “alimentary limb”. The continuity of the intestine is restored via a jejuno-jejunal 
anastomosis between the alimentary limb and the excluded biliopancreatic limb 
approximately 75–150 cm distal to the gastrojejunostomy 3. As a result, food 
bypasses most of the stomach, the entire duodenum, and the proximal jejunum. 
VSG involves dividing the stomach along its vertical length to create a sleeve and 
removing ∼75% of its volume 4. Although decreasing in popularity, the adjustable 
gastric banding (AGB) involves placing a silicone ring around the proximal stomach, 
bellow the gastroesophageal junction. The ring pressure is adjusted through fluid 
injected or withdrawn from a subcutaneous port 5.  
Efficacy is not the same among procedures, as RYGB and VSG cause more weight 

















from improvements in glycaemic control 7, reduced cardiovascular morbidity and 
mortality 8 and reduced incidence of cancer 9. All three procedures cause no 
mechanical restriction with little or no macronutrient malabsorption. Instead, weight 
loss is due to changes in the physiology of body weight regulation.  
In this review, we will explore the biological mechanisms underpinning weight loss. . 
We will not discuss the mechanisms underlying glycaemic/metabolic improvements 
as they fall outside the already wide scope of this review. The impact of obesity 
surgery on metabolism appears to be predominantly because of the substantial and 
sustained weight loss, but given the large number of mechanisms which are not 
weight loss related we expect that the beneficial metabolic outcome at individual 
level may be a composite of the weight loss together with non-weight loss related 
mechanisms.   
We will focus on mechanistic studies in humans and animal models focusing on 
RYGB, VSG and AGB, as they are the most commonly performed operations. While 
animal data may not always apply to humans, they also raise new questions that can 
be answered in humans and answer questions that cannot be answered in humans. 
Mechanisms underlying weight loss after obesity surgery (RYGB, VSG, AGB) 
a. Eating behaviour   
i. Reduction in energy intake  
 
The setpoint theory supports the notion that an individual’s body weight trajectory 
during life is predominantly influenced by their genetic make-up, which interacts with 
non-biological factors (e.g., social, psychological) to determine the final phenotype 10. 

















areas of the brain that regulate energy intake and expenditure, such as the 
hypothalamus and brainstem 11. These areas are located in the subcortical areas of 
the brain involved in automated function like respiration or body temperature. The 
hypothalamus and brainstem receive continuous and highly accurate humoral and 
neural signals from adipose tissue, stomach, intestine and pancreas regarding body 
energy stores and acute energy intake respectively. Upon weight loss, these 
messengers change and 12 signal depletion of body energy stores which is 
disadvantageous from an evolutionary perspective. The final common pathway of 
this mechanism is the defence of the individual’s body weight setpoint through an 
increase in hunger and reduction in satiety which trigger the executive function areas 
located in the cortical areas of the brain to seek and consume food.   
A good example of how this system is activated is intentional weight loss through 
caloric restrictive diets. People on severe caloric restriction frequently report a 
decrease in hunger and increase in satiety during the acute phase of negative 
energy balance. However, the vast majority find it difficult to maintain the weight they 
have lost when it plateaus during the  stable energy balance phase. This is despite 
the cortical areas of the brain that control dietary restraint working intensely to 
maintain the body weight lost. The increase in hunger and decrease in satiety 
signalled by the hypothalamus/ brainstem results in an increase in caloric intake 
which eventually leads to the regain of weight lost and in many cases the 
establishment of a new setpoint which is higher than the original baseline 12. 
Repeated cycles of this process increase body weight setpoint, making it 
progressively harder to achieve sustained weight loss 13. Consequently, any 

















from a biological perspective, to counteract this elaborate body weight regulation 
system. 
Obesity surgery has proven to be biologically very sophisticated and is thus an 
effective therapy. Similar to caloric restriction during the acute negative balance 
phase, patients after surgery report a decrease in hunger and increase in satiety 14. 
The key difference between dieting and obesity surgery is that after surgery, the 
body weight setpoint is reduced by approximately 20-30% 15. Manipulation of the 
stomach and the small intestine result in favourable changes in humoral and neural 
signals from the gut to the brain that are conducive to the maintenance of this newly 
established body weight setpoint.  
The comparison of patients’ reports and actual weight during the plateau phase of 
weight loss during dieting vs. obesity surgery is intriguing. Even after surgery, 
patients report an “alarming” increase in hunger and decrease in satiety during the 
stable energy balance phase and indeed this translates in both higher energy intake 
during meals and an increase in meal frequency 16. Yet, body weight increases only 
marginally and never reaches the pre-operative value in the majority of cases. Whilst 
at this new set point, the intensity of the internal feelings of hunger and satiety might 
return to almost pre-operative levels, altered signalling from the gut acts continuously 
to reduce total energy intake during a 24-hour period in order to robustly defend the 
new normal 12.  
 
Patients losing weight through pharmacotherapy (e.g. with glucagon-like peptide 1 
(GLP-1) receptor agonists) report very similar changes in their appetite during the 

















the effect size of pharmacotherapy is lower than that of surgery, and that is because 
medications change only one or few of the signalling pathways in the appetite 
centres of the brain.  
Weight loss after the biliopancreatic diversion further highlights that the mechanisms 
through which these operations work are physiological and not “cognitive" in nature. 
This procedure is the most effective operation for weight loss, but rarely performed 
these days due to the associated severe nutritional complications. The very long 
intestinal bypass in this procedure results in frank macronutrient malabsorption and 
weight loss. The brain appetite centres rapidly detect this and compensate by 
increasing hunger. Patients after the biliopancreatic diversion commonly consume 
more calories compared to before their operation. However, even this hyperphagia is 
not enough to compensate for the severe loss of calories through the gut which is 
therefore the dominant mechanism causing weight loss.  
 
Neural correlates of reduction in energy intake  
The hypothalamus is a critical brain area that controls energy intake and expenditure 
via two sets of antagonistic neurons: agouti-related peptide (AgRP) neurons to 
promote hunger and pro-opiomelanocortin (POMC) neurons to promote satiety 18 
(Figure 1). Neuropeptide Y (NPY) is secreted by AgRP neurons and is an orexigenic 
factor.  Hypothalamic gene expression of Agrp, Npy and Pomc changes following 
RYGB surgery 19, 20, but the findings are not consistent and often lack a weight-
matched calorie restricted model. Expression levels of hypothalamic Agrp in obese 
female rats are upregulated when compared to lean controls, but go down to levels 

















21. A recent study investigated the expression of hypothalamic NPY and AgRP in 
obese mice, following RYGB and compared the results to a weight-matched model. 
During the first two post-operative weeks, when the peak weight loss was observed, 
hypothalamic Agrp and Npy gene expression did not increase compared to mice 
undergoing sham surgery, suggesting that compensatory hunger signals in the 
RYGB mice were not activated. In contrast, when the same amount of weight loss 
was achieved by caloric restriction in a different group of mice, increased expression 
of Agrp and Npy was observed. Of note, Pomc expression was not altered to a 
similar degree as Agrp, indicating that RYGB suppresses the adaptive hunger 
response triggered by weight loss 22-24. Similarly, VSG does not change Npy and 
Agrp gene expression in obese rats 4 weeks after surgery 25. A study that compared 
VSG and AGB-treated obese rats six weeks after surgery showed that the 
hypothalamic expression of Npy was significantly lower and the expression of Pomc 
was significantly higher in the VSG group 26. Given the similar post-operative time 
points, any discrepancies between these studies’ findings on Agrp, Npy and Pomc 
may be due to rodent strain, differences, diet type and length of exposure, and 
variations in surgical technique. 
The brainstem is the other key player in the obesity surgery-induced suppression of 
hunger. The strong orexigenic drive stemming from arcuate AgRP/NPY neurons may 
partly result from inhibition of an equally strong feeding anorexia circuit organized 
around the lateral parabrachial nucleus (lPBN) and brainstem 27, 28. Measurement of 
meal-induced neuronal activation by means of c-Fos in obese mice showed that 
brainstem anorexia circuit may have a potential role in adaptive neural and 
behavioural changes involved in the strong early suppression of energy intake after 

















These findings from animal models support the observations from humans in that the 
direction of change in expression of neuropeptides in the hypothalamus and 
brainstem after RYGB and VSG is opposite to dieting and favour the maintenance of 
a lower body weight set point.  
 
Neural signalling 
The mechanism of action of AGB is thought to be exclusively through vagal 
signalling. Injection of fluid through the subcutaneous port increases the extra-
luminal pressure on vagal afferents, sending an anorexigenic signal to the brainstem, 
even in the fasting state 30. This mechanism is further exaggerated through the 
increase in fundal intra-luminal pressure exerted by the consumption food, leading to 
early satiety during a meal. It is common for healthcare professionals to inject 
progressively more fluid in the AGB in patients not losing enough weight. This 
eventually leads to mechanical restriction and vomiting. This is a preventable 
complication that should be avoided, and instead an early decision should be made 
to remove the AGB in patients who do not respond. More patients do not respond to 
the AGB compared to RYGB/VSG 31 because the AGB activates only one signalling 
system to the brain, as opposed to the plethora of anorexigenic signals after 
RYGB/VSG. A study in rats suggested that signals carried by vagal afferents from 
the mid and lower small intestine contribute to the early RYGB-induced body weight 
loss and reduction of food intake 32. Disruption of vagal afferents and/or efferents 
takes place during RYGB and VSG surgery; whether this affects appetite and post-
operative weight loss remains unclear. Some studies suggested that vagal sparing 

















should be preserved during the gastric bypass operation 33, 34. However, there are 
limited data on the role of vagus nerve dissection in RYGB and VSG with regards to 
body weight in humans 35.  
 
ii. Food selection  
 
After RYGB and VSG surgery, but not AGB, some patients also change their food 
selection 36. This includes a shift in preference from energy-dense sweet and fatty 
food to less energy-dense options. The majority of research in this area has used 
indirect measures of behaviour, e.g. questionnaires, food diaries and verbal report at 
recall sessions. Whilst these have suggested that the reduction of the consumption 
of energy dense food might be an additional weight loss mechanism after surgery, 
they have also demonstrated large variations in response and substantial 
heterogeneity in findings 37. This is particularly noticeable in the longer-term 
measurements of eating behaviour, 5-10 years after surgery when any early 
changes in macronutrient selection tend to dissipate.  
Only a small number of studies have used direct measurements of eating behaviour, 
i.e., observing the participant’s choices during an ad libitum meal or an eating 
behaviour task. The best evidence so far suggests that patients who lost more 
weight were those who consumed a lower percentage of fat and low-glycaemic index 
foods, and higher percentage of protein as a proportion of their total daily caloric 

















The reduction in the rewarding properties of food is one of the mechanisms that 
underpins the changes in food selection (Figure 2). This mechanisms has been 
investigated using functional neuroimaging. Functional Magnetic resonance imaging 
(MRI) and Positron Emission Tomography (PET) studies provide information both 
with respect to the direction of change and the areas of the brain reward system that 
correlate with changes in observed or reported eating behaviour. Notwithstanding 
discrepancies between studies, there is some agreement that there is a reduction in 
the activation of brain areas that respond to the involved cues with rewarding 
properties  (e.g. food pictures) after RYGB and VSG 39, 40. The effect size of this 
reduction is more pronounced after RYGB compared to VSG 41. Gut hormones are 
mediators that underlie this observation, as the blockage partly reverses the 
reduction in activation of these brain regions 42. This is in line with animal and human 
data demonstrating that gut hormones such as glucagon-like peptide-1 (GLP-1) and 
peptide YY (PYY) do not just reduce hunger and increase fullness, but reduce the 
rewarding properties of food through their direct action on their receptors in brain 
reward areas 43. It should be noted that functional neuroimaging findings should be 
interpreted with some caution as they only measure neural correlates of eating 
behaviour, not behaviour itself. The available paradigms also do not allow enough 
granularity as to whether measured brain responses to food pictures reflect 
appetitive or consummatory behaviour.  
Altered taste function is another mechanism underlying the changes in food selection 
after RYGB and VSG. With regards to the sensory domain of taste, acuity for sweet 
taste is heightened only in the early post-operative period. 44. It is therefore unlikely 
to be responsible for long term effects. Selective changes in the appetitive reward 

















RYGB and VSG, i.e. during the acute phase of negative energy balance 45, 46, but 
these findings have not been replicated in animal models of RYGB during the stable 
energy balance phase 47. The valid measurement of the consummatory reward value 
of taste is challenging in humans as it relies entirely on the use of indirect measures 
like visual analogue scales (VAS). Studies using VAS after RYGB surgery have 
shown discrepant results 44, 48. There is more consistency in the rodent literature, in 
which orofacial responses, a good marker of consummatory responses,  increase for 
low concentrations of glucose and decrease for high concentrations of glucose after 
RYGB 49, 50. The third domain of taste function is termed digestive preparation and 
salivation is a marker of this reflex response to tastants. Rates of salivation correlate 
with the rewarding aspects of the tastant and people with obesity demonstrate higher 
salivation rates to normal-weight controls 51. Attempts have been made to measure 
salivation rates after obesity surgery but with mixed results 52. Our group’s 
experience with measuring salivation rates in humans is that the available 
methodologies suffer from low reproducibility (unpublished data). 
Neural signalling also contributes to changes in the rewarding value of fat and sugar 
after surgery. This was investigated in obese rats undergoing RYGB as they were 
found produce less of the fat-satiety molecule oleoylethanolamide in the small 
intestine, and this effect was associated with vagus nerve-driven increases in dorsal 
striatal dopamine release 53. Inhibition of local oleoylethanolamide, vagal, and dorsal 
striatal dopamine-1 receptor signalling was inhibited, the beneficial effects of RYGB 
on fat intake and preferences was reversed.  
Post-ingestive neural signalling, in the form of what is widely known as dumping 
syndrome, may contribute to the underlying reductions in high-glycaemic index or 

















of nausea, sweating and dizziness early after consumption of sugary or fatty foods, 
which in some people may result in conditioned taste avoidance 54. During this 
learning process, these unpleasant symptoms are presumably generated through 
osmotic shifts between the intestine and circulation, and altered neural signalling. 
These symptoms are usually associated with the ingestion of specific foods. This 
does not lead to the complete extinction of these foods from regular consumption, 
i.e., aversion, but rather their avoidance. Thus the foods remain pleasant to the 
subject but only when consumed in smaller quantities 54. It should be noted that 
dumping syndrome is not present in all patients after RYGB and it may indeed be the 
case that its impact dissipates over time. This might be due to intestinal adaptation 
that continues to take place for years after surgery. Dumping is less common after 
VSG and AGB 55, operations not involving duodenal bypass. 
Overall, the available data suggest that changes in food selection take place in a 
proportion of people after RYGB and VSG, but not after AGB. In the former, this 
mechanism could compliment the reduction in hunger and increase in satiety to 
cause additional weight loss. Whether this mechanism persists over time or 
dissipates following intestinal adaptation remains uncertain. The process of learning 
to avoid foods that generate unpleasant post-ingestive effects has a greater impact 
than taste function in shaping food preferences after surgery. Some of the above 
unresolved questions could be answered using residential stays in facilities that 
allow human eating behaviour to be as close to normal as possible. Such 
experiments could be conducted both early and late after surgery and complimented 


















b. Energy Expenditure 
 
Enhanced energy expenditure after obesity surgery may be a contributing 
mechanism to weight loss. Resting energy expenditure has been measured in 
humans following RYGB, and most recent studies using indirect calorimetry show 
resting energy expenditure to either decrease within the first post-operative year 56-
58, remain stable 59 or even slightly increase 60. These changes are reported to be 
highly dependent on organ-tissue body composition as RYGB patients maintain a 
larger high-metabolic rate organ mass than non-operated controls 59. Moreover, the 
acute weight loss following obesity surgery was found to affect the accuracy of 
energy expenditure predictive equations 61.  
A small number of studies used 24-hour indirect calorimetry, a method that is optimal 
for measuring substrate oxidation because each subject can freely move, consume 
meals, and engage in physical activity. One study reported that diet-induced energy 
expenditure in patients 20 months after RYGB was increased, which resulted in an 
increased contribution to total energy expenditure over 24 hours from an average 
12.9 cal/min/kg to 14.7 cal/min/kg, when corrected for total tissue mass, including 
total adipose tissue, lean body mass, bone mineral density and bone mineral content 
62. Another study reported no changes in 24-hour or diet-induced energy expenditure 
11 weeks after RYGB, although this was not corrected for total tissue mass 63. Nine-
years after RYGB, patients had greater diet-induced energy expenditure and total 
24hour energy expenditure at an average of 16.9 cal/min/kg when compared to 
Vertical Banded Gastroplasty patients, a procedure similar to AGB, at 14.9 
cal/min/kg 64. At a shorter follow up period, 24-hour energy expenditure was 

















underwent RYGB, VSG, AGB and very low-calorie diet, following adjustment for 
decreases in fat-free mass and fat mass. However, this effect persisted up to one 
year only after RYGB and VSG (RYGB, −124 ± 42; VSG, −155 ± 118 kcal/d) 65. 
Additionally, patients who underwent biliopancreatic diversion (consisting of a 
horizontal gastrectomy with a distal Roux-en-Y reconstruction resulting in an 
alimentary limb of 250 cm and a common channel of 50-100 cm) demonstrated 
increased diet-induced (11.0% at baseline to 19.9% of caloric intake) and physical 
activity (8344.3 at baseline to 9701.4 kcal/24hr) related-thermogenesis at 6-months 
postoperatively, when compared to an unoperated control group 66. One mechanism 
which may contribute to increased energy expenditure during a meal in humans may 
be the enhanced glucose utilisation by the hypertrophied small intestine 67. However, 
absolute energy expenditure is reduced after surgery in humans and the increase in 
energy expenditure expressed per total body m ss may be at least in part explained 
by change in body composition (i.e. increased lean to fat mass ratio). 
The type of diet may also affect measurements of energy expenditure. A randomised 
clinical trial in patients following diet-induced weight loss showed that lowering 
dietary carbohydrate intake increases energy expenditure during weight loss 
maintenance 68. However, meta-analysis of 32 controlled feeding studies with 
isocaloric substitution of carbohydrate for fat found that both energy expenditure and 
fat loss are greater with lower dietary fat 69. 
Contrary to observations in humans, the majority of studies in rodent models of 
RYGB report an increase in total energy expenditure when compared with ad libitum-
fed shams and weight-matched shams. This has been measured at different post-
operative time points using indirect calorimetry or validated mathematical formulae 

















However, indirect calorimetry produces an absolute error as high as 38% when 
compared with standard direct calorimetry 74. A recent study 75 used a combination 
of sensitive direct and indirect calorimetry to overcome this limitation and 
demonstrated an increase in resting energy expenditure after RYGB, but not VSG. 
Brown adipose tissue (BAT) is a major player in regulating energy metabolism by 
thermogenesis and triglyceride clearance 76, 77 and plays a role in energy expenditure 
changes after obesity surgery. A decrease in triglyceride content, coupled with 
increased proportion of brown adipose tissue in the supraclavicular fat depot was 
found in women six months after RYGB and VSG 78. However, the role of BAT in 
energy expenditure following obesity surgery has mainly been studied in rodents. 
The expression of key BAT thermoregulatory genes such as uncoupling protein-1 
(UCP-1), remain unchanged following RYGB but are reduced in caloric-restricted 
weight-matched animals 79, and that the bypassed duodenum has a key role in the 
observed postoperative metabolic profile 80. The volume and metabolic activity of 
BAT, as recorded by micro-positron emission tomography/computed tomography 
increased following RYGB, but not after AGB and VSG 81. A proposed mechanism 
for the metabolic activity of BAT is an observed increase in growth hormone/insulin-
like growth factor-1, which regulates adipocyte differentiation 81. Unlike VSG, RYGB 
causes an increase in total resting metabolic rate, as well as a specific increase in 
splanchnic sympathetic nerve activity and “browning” of visceral mesenteric fat via 
endocannabinoid signalling within the small intestine 75. Although in vivo studies are 
vital to unravel the mechanisms of energy expenditure difference after obesity 
surgery, it is important to note the species difference between mice and rats, as well 
as strain differences in a single species. There are also differences between rodent 

















amount and thermogenic capacity 82. Despite this, UCP1 content and function are 
similar between human and mouse BAT 83. 
Overall, it remains unclear from the existing evidence to what extent, if at all, post-
operative weight loss is driven by enhanced energy expenditure after RYGB and 
VSG versus dietary calorie restriction, as energy metabolism is closely associated 
with body weight changes. The discrepancy on energy expenditure values reported 
in the discussed studies could indeed be due to differences in diet, patient body 
composition and energy expenditure measurement. These uncertainties suggest to 
us that the physiological contribution of energy expenditure to weight loss after 
RYGB and VSG is small in comparison to the dominant contribution of reduced 
energy intake.   
 
Mediators underlying changes in energy intake and expenditure 
after obesity surgery 
a. Gut hormones 
 
Gut hormones are secreted in response to nutrient ingestion and regulate energy 
balance and glucose homeostasis by signalling to the pancreas but also by direct 
and indirect action in the brainstem and the hypothalamic arcuate nuclei 84. Two 
anorexigenic gut hormones that have been widely investigated after obesity surgery 
are GLP-1 and peptide YY (PYY) which are secreted by the enteroendocrine L-cells 

















Both GLP-1 and PYY are elevated post-prandially after RYGB and VSG, and the 
enhanced secretion has been hypothesised to be a key mediator of the observed 
post-operative increase in satiety 85. Fasting concentrations do not change 
significantly, suggesting that they are not the mechanisms underlying the reduction 
in hunger. The absence of mechanical restriction at the level of the gastro-jejunal 
anastomosis after RYGB enables the rapid delivery of nutrients to the jejunum and 
ileum, where the highest number of enteroendocrine (primarily GLP-1 secreting) L-
cells are located, triggering the enhanced secretion of anorexigenic gut hormones 86. 
These exert their action in the brainstem/hypothalamic system through stimulation of 
intestinal vagal afferents and by crossing the blood-brain barrier. Despite the 
absence of intestinal bypass, VSG is thought to engage the same mechanism 
through the rapid emptying of the high-pressure gastric remnant 87, thus creating a 
functional intestinal bypass. However, the post-prandial increase in anorexigenic gut 
hormones after VSG is lower to that observed after RYGB 88. This might explain 
differences in the weight loss efficacy of the two interventions and substantial weight 
regain after VSG at long term follow-up. Despite the persistent rapid delivery of 
nutrients to the distal small intestine, there is no compensatory decrease in the L-cell 
numbers after RYGB 86. In contrast, following intestinal adaptation L-cell numbers 
increase, further amplifying anorexigenic signalling. The density of enteroendocrine 
cells in the distal small intestine does not change as the intestinal volume also 
increases through hypertrophy 86.  
Combined blockade of both GLP-1 and PYY via single infusion of antagonists 
increases energy intake, pointing at their appetite-suppressing role in humans after 
RYGB 89. These findings are in line with experiments in which the administration of 

















in suppression of postprandial secretion of PYY and GLP-1 and reduction in energy 
intake only in the RYGB group 14. 
Chronic infusion of the selective GLP-1 receptor antagonist exendin-(9-30) into the 
lateral cerebral ventricle significantly increased energy intake and body weight in 
both RYGB and sham-operated rats, while chronic infusion of a selective Y2-
receptor antagonist had no effect in either group 90. However, obese GLP-1R-
deficient mice (GLP-1-/-) lost the same amount of body weight and fat mass and 
maintained a similarly lower body weight compared with wild-type mice, following 
RYGB 90. This observation indicates low importance of GLP-1R in appetite regulation 
and this was further confirmed by blocking peripheral and central GLP-1R action in 
RYGB and sham obese mice using exendin-(9-30), which did not reverse the weight 
loss effect of RYGB or influence the weekly body weight gain in sham mice 91. 
Similarly, obese Y2-receptor deficient mice (PYY-/-) also responded similarly to 
RYGB compared to wild type mice for up to 20 weeks after surgery, with initial 
hypophagia and sustained body weight loss. Weight-matched Y2-R knockout mice 
showed the same improvements to RYGB as seen in wild type mice, suggesting that 
PYY signalling through Y2 receptor alone is not responsible for the appetite-
suppressing and body weight-lowering effects of RYGB 92. However, acute 
administration of exendin-(9-30) with a selective Y2-R antagonist increased high fat 
food preference additively in RYGB-operated but not in sham-operated diet-induced 
obese rats 93. This is in agreement with human studies 89, 94 and indicates a 
differential effect of antagonists when administered alone versus in combination, as 
well as acutely versus infused chronically. This also contrasts an  acquired effect 
associated with antagonist infusion , compared to the genetic state associated with 

















Recent studies have focused on two additional gut hormones: oxyntomodulin and 
glicentin, products of the pre-proglucagon gene also released from enteroendocrine 
in response to food transit. Oxyntomodulin is a dual agonist of glucagon and GLP-1 
receptors that may act additively to GLP-1 to reduce food intake and appetite95. 
Glicentin protein sequence contains the sequence of oxyntomodulin and lthough its 
biological role is not yet clear, it is hypothesized to be the most stable of the 
proglucagon peptides and therefore may serve as the best marker of the secretion of 
L-cell hormones, such as GLP-1 88. Postprandial levels of oxyntomodulin and 
glicentin were significantly increased three months after VSG or RYGB, but not after 
AGB, in humans, and  these elevated concentrations were positively associated with 
feeling of satiety and weight loss 96. These  results were later replicated by Nielsen et 
al, who reported that elevated circulating levels of oxyntomodulin and glicentin 
predicted weight loss and were positively associ ted with a decreased preference for 
energy-dense foods 88.  
Changes to plasma concentration of the orexigenic hormone ghrelin after RYGB 
remains controversial. Studies in humans have demonstrated that hormone levels 
are increased, decreased or stay the same 97. The results of studies measuring 
ghrelin after VSG are more consistently demonstrating a decrease in the post-
prandial concentrations of the hormone 97. Thus, the contribution of ghrelin 
reductions in weight loss might be more relevant after VSG than RYGB. 
b. Bile Acids 
Bile acids have long been known to play an important role in dietary lipid absorption 
and cholesterol catabolism and have been shown to increase energy expenditure by 
promoting intracellular thyroid hormone activation 98. Bile acid function is mediated 

















receptor A (FXR). These receptors stimulate the postprandial release of fibroblast 
growth factors 19 and 21 (FGF19/21) 99. FGF19 is released from the small intestine 
post-prandially and decreases bile acid secretion, while FGF21 is secreted by the 
liver during fasting and has a role in energy homeostasis maintenance, as well as 
controls glucose and lipid metabolism (Figure 3). Circulating FGF19 levels have 
been shown to be lower in people with obesity compared to healthy control subjects 
100, while administration of human FGF19 in obese mice induced a significant dose-
dependent decrease in body mass which was associated with a decrease in the 
concentrations of triglycerides, as well as increased fatty acid oxidation and brown 
tissue mass 101. Following the release of FGF19, the role of subsequent neuronal 
FGF receptor activation has also been linked to body weight regulation, as it signals 
an energy-replete state to hypothalamic AgRP/NPY neurons 102. In contrast, FGF21 
is elevated in people with obesity 103, and obese mice are insensitive to exogenous 
FGF21 administration, suggesting that obesity is an FGF21-resistant state 104. 
However, FGF21 sensitivity is restored in humans following weight loss 105. Although 
not directly correlated with obesity, FGF21 variants are associated with increased 
sweet consumption, as plasma FGF21 levels increase acutely after oral sucrose 
ingestion. This indicates that FGF21 could influence eating behaviour 106. 
Total bile acids and FGF19 increase after RYGB and VSG in humans and rodents 
107. Specifically, glycine-conjugated serum bile acids increased acutely following 
RYGB in humans, while both conjugated and unconjugated bile acids increased after 
VSG, an effect not replicated in an unoperated calorie-restriction control group 108, 
109. The bile acid increase is sustained five years after surgery, with higher levels 
associated with greater weight loss, and lower total cholesterol 110. Apart from their 

















thought to have an appetite-inhibitory effect, as they stimulate the secretion of GLP-1 
and PYY 111. However, serum bile acids, FGF19 and GLP-1 concentration all 
decreased in patients who achieved lifestyle-induced weight loss, further pointing to 
the fact that dieting and obesity surgery-induced changes in body weight are 
triggered by different mechanisms 112. Discrepancies exist regarding the post-
operative timing of bile acid increase, as some studies report an acute effect 109 
whether others observe a gradual increase 1 year following surgery 113, 114. 
Concentrations of FGF21 after surgery remain more controversial between different 
studies, possibly because circulating concentration and sensitivity changes are 
shown to be secondary to weight loss which can differ widely 99, 115-117. 
A growing body of evidence suggests that circulating bile acids act as signalling 
molecules that control both their own synthesis and multiple metabolic pathways by 
targeting the transcription factor FXR and the membrane protein TGR5. FXR 
appears to be key in post-operative weight loss, as it controls the transcription of 
genes involved in fatty acid and triglyceride synthesis and lipoprotein metabolism 118 
and promote adipose tissue browning 119. In vivo studies involving genetic disruption 
of FXR in mice that then underwent VSG demonstrated that the receptor is a 
molecular target for beneficial effects of surgery as it contributes to the maintenance 
of weight loss following VSG. Specifically, FXR-knockout VSG mice consumed more 
energy than sham operated controls suggesting that FXR signalling is necessary for 
the repression of rebound hyperphagia following caloric restriction initially achieved 
by VSG 120. Studies in mice also investigated the role of TGR5 receptor in post-
operative weight loss, as its activation can increase postprandial GLP-1 secretion in 
the lower intestine 121, 122. Similar to FXR studies, TGR5 knockout mice 

















analysis revealed no differences between wild type TGR5-knockout sham and VSG 
mice at 14 weeks after surgery, indicating that TGR5 is required to maintain weight 
loss and fat mass reduction after VSG 123. A possible mechanism of this is a TGR5-
driven mitochondrial separation and turnover of white adipose tissue to beige, as 
administration of TGR5-selective bile acid mimetics to thermoneutral housed mice 
led to the appearance of beige adipocyte markers and an increase in mitochondrial 
content 124. However, not all studies report a reduction of weight loss following VSG 
and RYGB in TGR5 knockout mice 125, 126. A possible explanation for this is the rate 
of weight regain following obesity surgery, and as a result, the type and length of 
exposure to high-fat diet in pre-operative mice. Most studies investigating the role of 
the TGR5 and FXR receptors were conducted in animal models, and their roles may 
be different in humans.  
Overall, the role of bile acids on post-operative weight loss is not yet fully 
understood. As the extent to which energy expenditure drives weight reduction 
following obesity surgery remains unclear, the ability of bile acids to increase GLP-1 
secretion 111 and the role of FGF19 on hypothalamic AgRP/NPY neurons 102 indicate 
an indirect anorectic effect as the main course of action after RYGB and VSG.  
 
c. Gut microbiota  
 
Gut microbiota have a vital role in both energy harvesting and energy expenditure.  
They can metabolize indigestible complex carbohydrates by fermentation, leading to 
the production of short-chain fatty acids, as well as control the absorption of nutrients 

















tissue and the turnover of beige adipocytes, as mice lacking gut microbiota have 
been reported to have impaired UCP1-dependent thermogenesis in cold, and oral 
gavage of the bacterial metabolite butyrate was able to rescue the effect with BAT 
recruitment 129.  
Obesity is often characterised by gut dysbiosis, as defined by substantial 
modifications in the gut microbiota composition and low microbial gene richness 130. 
Firmicutes and Bacteroidetes are the two dominant gut microphyla associated with 
obesity 131, and the Firmicutes/Bacteroidetes ratio correlates with increased body 
weight 132. Together these phyla account for 90% of the microbiome, with the 
remaining groups separated mainly into Actinobacteria, Proteobacteria and 
Verrucomicrobia 133. Akkermansia muciniphila of class Verrucomicrobia has also 
been correlated with obesity in humans 134.  
The mechanism via which obesity surgery achieves weight loss may include 
changes in gut microbiota. Transfer of gut microbiota from RYGB-treated mice to 
non-operated, germ-free mice resulted in weight loss and decreased fat mass in the 
recipient animals when compared to recipients of microbiota induced by sham 
surgery 135. In rats transplanted with the RYGB-microbiota, this decrease in adiposity 
and body weight was not associated with a change in food intake, further suggesting 
that the RYGB-associated gut microbiota either increase energy expenditure or have 
reduced ability to harvest energy from nutrients 135. Stool transplantation from 
patients after RYGB or Vertical Banded Gastroplasty (VBG) to germ-free mice 
promoted reduced fat deposition and weight gain when compared to a control group 
that was colonized with stools from patients with obesity 136.   Mice colonised with 
obesity surgery microbiota also had a lower respiratory quotient, indicating 

















Although human studies 137, 138 have reported differences in gut microbiota post-
operatively, the extent of these changes varies. This could be due to patient 
inclusion criteria, such as glycemia state and medication, but also diet, and type of 
procedure. However, studies in humans consistently demonstrate an increase in gut 
microbiota diversity, spatial organization and stability, and specifically 
Proteobacteria, after RYGB (Table 1). Gut microbiota diversity is a measure of how 
many different species exist and how evenly distributed they are in the gut 
community, and low diversity is a sign of dysbiosis 139. Some studies also reported a 
decrease in Firmicutes and Bacteroidetes phyla in humans and rats post RYGB 136, 
140, 141. Increase in gut microbiota diversity, stability and resilience is important, as a 
large number of associations between gut microbiota and adipose tissue gene 
regulation as early as three months after surgery 136, 140, 142 have been reported, 
further demonstrating that gut microbiota may play a direct role in the control of 
adiposity by regulating lipid metabolism. Moreover, gut microbiota lead to the 
production of short-chain fatty acids, which stimulate GLP-1 secretion via free fatty 
acid receptor-2 (FFAR2), and therefore may also reduce energy intake 143. 
A decrease in Proteobacteria was recorded in patients following VSG 144 and AGB 
145. This differential effect between VSG and RYGB could be a result of duodenal 
exclusion in RYGB, as duodenal-jejunal bypass with minimal gastric resection in 
obese rats increased microbial richness and abundancy when compared to rats 
treated with GLP-1R agonists 146, 147. This has also been observed in humans 
following treatment with the endoscopic duodenal-jejunal bypass liner 148 149. 
Comparison of AGB, pharmacologically induced weight loss and RYGB 
demonstrated that at similar weight loss, the greatest alteration in gut microbiota 

















Despite the positive effect on weight loss through a combination of mechanisms 
discussed above, RYGB is unable to fully reverse the decreased gut microbial gene 
richness and compositional changes observed in patients with obesity 151. 
Interventions such as faecal transplantation from lean donors to patients with obesity 
revealed that weight-lowering beneficial effects are linked to changes in plasma 
metabolites and driven by baseline faecal microbiota composition 152. Moreover, gut 
microbiota diversity alteration accelerates post-dieting weight regain 153, suggesting 
that microbiome-targeting approaches may help enhance weight loss after surgery or 
prevent weight regain.  
 
Genetics and Obesity Surgery 
Patient selection for surgery (“personalized medicine”) may provide an additional 
refinement for existing procedures and could lead to the identification of genes or 
pathways which might provide useful therapeutic targets. Candidate gene studies 
have explored roles for the melacocortin-4 receptor (MC4R) 154, revealing greater 
weight loss in patients whose obesity is in part driven by mutations in this gene. A 
more recent genome-wide association study (GWAS) 155 has reported 17 single 
nucleotide polymorphisms (SNPs) in weight loss two years post RYGB, implicating 
roles for the 5-hydroxytriptamine receptor 1A and other genes. Whether the strength 
and number of these associations is substantial enough to provide predictive power 




















The anatomical manipulations during the most frequently used obesity surgery 
procedures cause weight loss through changes in the biology of the gut. Altered 
signalling from the gut to the brain, the organ responsible for the disease of obesity, 
facilitate reductions in energy intake and in some people changes in food selection. 
Increased or unaltered energy expenditure in the context of weight loss may also 
contribute to the defence of a new body weight set point. The precise mechanisms 
underlying these profound changes are not completely understood. Unravelling of 
the elusive physiology of the gut after surgery will help optimise surgical procedures, 
develop non-surgical therapies, address weight regain after surgery, but also 
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Table 1: Summary of selected publications reporting gut microbiota changes 
following bariatric surgery.  
Graphical Abstract: Representation of the main physiological mechanisms underlying 
weight loss following Vertical Sleeve Gastrectomy (VSG) and Roux-n-Y Gastric 
Bypass (RYGB). Abbreviations: GLP-1, glucagon like peptide-1; PYY, peptide YY. 
Figure was created using Servier Medical Art. 
 
Figure 1: The “AgRP-POMC” model of gut-brain cross-talk. Abbreviations: AgRP, 
agouti-related peptide; , POMC, pro-opiomelanocortin; NPY, Neuropeptide Y. Figure 
was created using Servier Medical Art. 
 
Figure 2: Changes in eating behaviour following obesity surgery 
 
Figure 3: Bile acid synthesis and receptor activation following obesity surgery. 
Abbreviations: FXR, Farnesoid X receptor; TGR5, G protein-coupled bile acid 
receptor 5; GLP-1, Glucagon-Like Peptide 1; FGF19, Fibroblast growth factor 19. 























 Obesity surgery induces significant weight loss, yet the exact mechanisms 
remain unclear 
 Changes in food selection take place after obesity surgery and this 
mechanism could compliment reduction in hunger and increase in satiety 
 Enhanced energy expenditure may be a contributing mechanism to weight 
loss, however reports are controversial 
 Post-prandial elevated secretion of anorectic gut peptides is considered to be 
a key mediator of the observed post-operative increase in satiety 
 Obesity surgery induces an increase in gut microbiota richness, which may 
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